Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Patients With Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation

NCT00532259 is registered in ClinicalTrials.gov with CureTech Ltd as lead sponsor.

NCT NCT00532259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00532259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Patients With Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation
Lead sponsor
CureTech Ltd
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2007
Completion date
August 31, 2011
Enrollment
72 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, large cell, diffuse, lymphoma, mixed cell, diffuse, primary mediastinal large b-cell lymphoma